{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.4","upperLimit":"25.2","value":"16.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"Calculated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide 50 mg/d on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\ncyclophosphamide: Given PO","id":"OG000","title":"Treatment (Bevacizumab, Cyclophosphamide)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from first day of treatment to time of death due to any cause, assessed up to 3 years","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}